100 FIFTH AVENUE, WALTHAM, MA
Notice of Supplemental Indenture, Fundamental Change and Make-Whole Fundamental Change to Trustee, Paying Agent, Conversion Agent and Holders of the 3.500% Convertible Senior Notes due 2026 (the “Notes”) (CUSIP: No. 03753U AB2)*
Apellis Pharmaceuticals Amends Executive Separation Benefits Plan
News, Reorganization Plan
Mikael Dolsten Elected to Board of Directors at Apellis Pharmaceuticals
Highlights Commercial Execution and Strategic Priorities at the 44th Annual J.P. Morgan Healthcare Conference
Material Contracts
Shareholder votes
Annual Report to Security Holders
Q1
Amended Annual Report
FY 2024
Q3
Q2
FY 2023
Notice of Suspension of Duty to File Reports
Tender Offer Statement by Third Party
Solicitation/Recommendation Statement
Tender Offer Statement by Issuer
Schedule 14D-9C Solicitation/Recommendation Statement Communication
Registration Statement for Securities to be Offered to Employees
Additional Proxy Materials
Definitive Proxy Statement
Amended Schedule 13G - Ownership Report
Statement of Changes in Beneficial Ownership
S-8 POS